Tag: cfDNA

Burning Rock Receives CE Mark

SHANGHAI, June 1, 2022 /PRNewswire/ — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) announced that it has received CE marking for its OverC™ Multi-Cancer Detection Blood Test manufactured in both the US and China facilities (Identification Number: DE/CA20/01-IVD-Luxuslebenswelt-523/22, DE/CA20/01-IVD-Luxuslebenswelt-524/22). OverC™ Multi-Cancer Detection Blood Test is a…

Continue Reading Burning Rock Receives CE Mark

Alpelisib Plus Olaparib Phase 1b Clinical Trial for Patients With Advanced Triple-Negative Breast Cancer

For a study, researchers sought to present the breast cancer cohort. In a previous study, they reported on safety. They recommended a phase 2 dose (RP2D) of olaparib combined with the PI3Kα-specific inhibitor alpelisib in patients with high-grade serous ovarian cancer as studied in a phase 1b trial (NCT01623349). Investigators…

Continue Reading Alpelisib Plus Olaparib Phase 1b Clinical Trial for Patients With Advanced Triple-Negative Breast Cancer

Plasma cfDNA predictors of established bacteraemic infection

Plasma cfDNA predictors of established bacteraemic infection | Microbiology Society 1887 This is a required field Please enter a valid email address Approval was a Success Invalid data An Error Occurred Approval was partially successful, following selected items could not be processed due to error Microbiology…

Continue Reading Plasma cfDNA predictors of established bacteraemic infection

Natera (NTRA) Presents New Data on Prospera and Renasight Tests

Get inside Wall Street with StreetInsider Premium. Claim your 1-week free trial here. Natera, Inc. (NASDAQ: NTRA) today announced that it has presented data on the clinical utility of the company’s Prospera™ and Renasight™ tests in 14 sessions at the American Transplant Congress (ATC) 2022 meeting. This expands on the…

Continue Reading Natera (NTRA) Presents New Data on Prospera and Renasight Tests

cfDNA-Based NGS IG Analysis in Lymphoma

Circulating cell-free DNA (cfDNA) is fragmented extracellular DNA, which is released from apoptotic and necrotic cells in small fragments of <200 bp [1]. cfDNA is typically isolated from the blood stream; however, it is also possible to detect cfDNA in other biological fluids such as urine or cerebrospinal fluid [2, 3,…

Continue Reading cfDNA-Based NGS IG Analysis in Lymphoma

Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

This article was originally published here Curr Oncol Rep. 2022 May 16. doi: 10.1007/s11912-022-01278-0. Online ahead of print. ABSTRACT PURPOSE OF REVIEW: The field of liquid biopsies is constantly evolving through novel technologies. This review outlines current data on liquid biopsies and application to clinical management of metastatic prostate cancer….

Continue Reading Integration of Liquid Biopsies in Clinical Management of Metastatic Prostate Cancer

Mulugeta Metaferia – Academia.edu

Mulugeta Metaferia – Academia.edu Academia.edu no longer supports Internet Explorer. To browse Academia.edu and the wider internet faster and more securely, please take a few seconds to upgrade your browser. Academia.edu uses cookies to personalize content, tailor ads and improve the user experience. By using our site, you agree to our…

Continue Reading Mulugeta Metaferia – Academia.edu

Comprehensive Evaluation and Application of a Novel Method to Isolate Cell-Free DNA Derived From Bile of Biliary Tract Cancer Patients

Cell-free DNA (cfDNA) exists in various types of bodily fluids, including plasma, urine, bile, and others. Bile cfDNA could serve as a promising liquid biopsy for biliary tract cancer (BTC) patients, as bile directly contacts tumors in the biliary tract system. However, there is no commercial kit or widely acknowledged…

Continue Reading Comprehensive Evaluation and Application of a Novel Method to Isolate Cell-Free DNA Derived From Bile of Biliary Tract Cancer Patients

CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting

CareDx, Inc. Data Highlights Clinical Utility of CareDx Solutions, Including Findings from Surveillance HeartCare Outcomes Registry (SHORE) Demonstrating Power of Multimodality Assessment for More Precise Interventions CareDx Symposia Feature Latest Advancements Including XenoSure and XenoMap SOUTH SAN FRANCISCO, Calif., April 20, 2022 (GLOBE NEWSWIRE) — CareDx, Inc. (Nasdaq: CDNA) –…

Continue Reading CareDx Showcases Leadership with Over 25 Oral Presentations and Posters at the International Society for Heart and Lung Transplantation Meeting

Early Experience Using Donor-derived Cell-free DNA for Surveillance of Rejection Following Simultaneous Pancreas and Kidney Transplantation

Background: Allograft biopsy is the gold standard for diagnosing graft rejection following simultaneous pancreas and kidney (SPK) transplant. Intraperitoneal biopsies are technically challenging and can be burdensome to patients and the healthcare system. Donor-derived cell-free DNA (dd-cfDNA) is well-studied in kidney transplant recipients; however, it has not yet been studied…

Continue Reading Early Experience Using Donor-derived Cell-free DNA for Surveillance of Rejection Following Simultaneous Pancreas and Kidney Transplantation

aCGH – Allie: Result by abbreviation

1  array comparative genomic hybridization(1473 times) Neoplasms(306 times) FISH (238 times)CNVs (135 times)MLPA (72 times) 2003 1-Mb resolution array-based comparative genomic hybridization using a BAC clone set optimized for cancer gene analysis. 2  array CGH(43 times) Neoplasms(12 times) CNVs (7 times)FISH (3 times)ID (3 times) 2003 Combined array comparative genomic hybridization and…

Continue Reading aCGH – Allie: Result by abbreviation

NIPT Testing For Pregnant Women

By Dr Niranjan Nayak, Consultant pathologist zonal technical chief west, Apollo diagnostic Pune Are you aware? Non-invasive Prenatal Testing (NIPT) means a screening test that can be done commonly in the first 3 months of pregnancy to detect chromosomal abnormalities in the baby. This test detects the 3 commonly occuring…

Continue Reading NIPT Testing For Pregnant Women

Bioinformatics analysis methods for cell-free DNA

This article was originally published here Comput Biol Med. 2022 Feb 3;143:105283. doi: 10.1016/j.compbiomed.2022.105283. Online ahead of print. ABSTRACT As a kind of novel non-invasive marker for molecular detection, cell-free DNA (cfDNA) has potential value for the early diagnosis of diseases, prognosis assessment, and efficacy monitoring. The constant developments in…

Continue Reading Bioinformatics analysis methods for cell-free DNA

A pilot study of the use of dynamic cfDNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas

The diagnosis of vitreoretinal lymphoma (VRL), a rare subtype of primary central nervous system lymphoma (PCNSL), is challenging. We aimed to investigate the mutational landscape of VRL by sequencing circulating tumor DNA (ctDNA) from aqueous humor (AH) and/or vitreous fluid (VF), as well as the application of ctDNA sequencing to…

Continue Reading A pilot study of the use of dynamic cfDNA from aqueous humor and vitreous fluid for the diagnosis and treatment monitoring of vitreoretinal lymphomas

Novel technologies in cfDNA analysis and potential utility in clinic

. 2021 Dec 31;33(6):708-718. doi: 10.21147/j.issn.1000-9604.2021.06.07. Affiliations Expand Affiliations 1 Department of Basic Medical Sciences, School of Medicine, Tsinghua University, Beijing 100084, China. 2 Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing 100730, China. 3 Department of Medical…

Continue Reading Novel technologies in cfDNA analysis and potential utility in clinic

Bioactive nanomaterials treat inflammatory bowel disease by scavenging multiple dangerous molecules

With the modernization of the Chinese people’s eating habits and lifestyles, the incidence of inflammatory bowel disease (IBD) has shown a sustained and rapid growth trend. The pathogenesis of IBD is complex, and clinical treatment is often dominated by anti-inflammatory drugs such as salicylic acid, glucocorticoids, and immunosuppressants, which have…

Continue Reading Bioactive nanomaterials treat inflammatory bowel disease by scavenging multiple dangerous molecules

Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells

This article was originally published here Ann Hematol. 2022 Feb 1. doi: 10.1007/s00277-022-04771-5. Online ahead of print. ABSTRACT With the advent of novel, highly effective therapies for multiple myeloma (MM), classical serologic monitoring appears insufficient for response assessment and prediction of relapse. Moreover, serologic studies in MM are hampered by…

Continue Reading Monitoring multiple myeloma in the peripheral blood based on cell-free DNA and circulating plasma cells

Comparison of circulating DNA in malignant neoplasia from diverse locations: Investigating a diagnostic role

Context: Circulating free DNA (cfDNA) analysis has emerged as novel noninvasive diagnostic biomarker in several solid tumors. Raised levels have been reported in several malignancies and may correlate with clinicopathological and treatment response. The current study was designed to assess the diagnostics of cfDNA in different tumor types of malignancies…

Continue Reading Comparison of circulating DNA in malignant neoplasia from diverse locations: Investigating a diagnostic role

Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care

This article was originally published here J Heart Lung Transplant. 2021 Dec 26:S1053-2498(21)02630-9. doi: 10.1016/j.healun.2021.12.009. Online ahead of print. ABSTRACT BACKGROUND: As a marker of underlying lung allograft injury, donor-derived cell-free DNA (dd-cfDNA) may be used to identify episodes of acute allograft injury in lung transplant recipients. We investigated the…

Continue Reading Donor-derived cell-free DNA as a composite marker of acute lung allograft dysfunction in clinical care

Why a huge NHS unit is on Nuneaton’s Asda car park

A huge NHS unit is on Nuneaton’s Asda car park as a trail-blazing trial of a new cancer-detecting blood test is under way. As we reported in our newsletter, the town was just one of a handful of areas across the Midlands to be picked as part of the pilot….

Continue Reading Why a huge NHS unit is on Nuneaton’s Asda car park

Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma

Interrogation of cell-free DNA (cfDNA) represents an emerging approach to non-invasively estimate disease burden in multiple myeloma (MM). Here, we examined low-pass whole genome sequencing (LPWGS) of cfDNA for its predictive value in relapsed/ refractory MM (RRMM). We observed that cfDNA positivity, defined as ≥10% tumor fraction by LPWGS, was…

Continue Reading Cell-free DNA for the detection of emerging treatment failure in relapsed/ refractory multiple myeloma

NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection

SOUTH SAN FRANCISCO, Calif., Jan. 07, 2022 (GLOBE NEWSWIRE) — CareDx, Inc.,  (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced the results of a study led by the National Institutes of…

Continue Reading NIH Study Shows Using CareDx’s AlloSure Lung for Transplant Surveillance is More Effective than Diagnostic Bronchoscopy at Identifying Rejection

Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases

doi.org/10.1038/gim.2017.56Get rights and content Abstract Purpose Invasive diagnostic prenatal testing can provide the most comprehensive information about the genetic status of a fetus. Noninvasive prenatal screening methods, especially when using cell-free DNA (cfDNA), are often limited to reporting only on trisomies 21, 18, and 13 and sex chromosome aneuploidies. This…

Continue Reading Genome-wide cfDNA screening: clinical laboratory experience with the first 10,000 cases

cfDNA ultra-deep sequencing with UMIs

cfDNA ultra-deep sequencing with UMIs 1 Dear all, I am analyzing sequencing data from a capture panel which uses UMIs. I did ultra-deep sequencing to detect variants in a very low VAF (less than 1%). This is an already fragmented DNA coming from plasma. After doing my pipeline using fgbio,…

Continue Reading cfDNA ultra-deep sequencing with UMIs

QIAseq cfDNA Library Kit, 96 reactions

QIAseq cfDNA Library Kit, 96 reactions   For 96 reactions on Illumina® sequencers: enzymes and buffers for cfDNA library prep, Illumina Adapter Plate 96-plex, Illumina Library Amplification Primer and PCR Master Mix   Features • Optimal conversion of cfDNA at every step from plasma to NGS library through highly efficient…

Continue Reading QIAseq cfDNA Library Kit, 96 reactions

Natera launches Prospera with quantification to improve kidney graft rejection testing

Natera has announced the launch of Prospera with quantification, the only cell-free DNA (cfDNA) test for kidney rejection that provides three values—the quantity of donor-derived cfDNA (dd-cfDNA), fraction of dd-cfDNA, and total cfDNA—on every report. Combining these three metrics has been shown to improve sensitivity when evaluating transplant rejection, compared…

Continue Reading Natera launches Prospera with quantification to improve kidney graft rejection testing

Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping was found to be noninferior to standard-of-care tissue-based genotyping for detection of guideline-recommended biomarkers and therapeutic outcomes in patients with advanced nonsquamous non–small cell lung cancer (NSCLC). Cell-free circulating tumor DNA (cfDNA)–based tumor genotyping is noninferior to tissue-based genotyping for detection of guideline-recommended…

Continue Reading Liquid Biopsy Noninferior to Tissue-Based Genotyping in Management of Advanced NSCLC

Scientist, Bioinformatics – Leonia | Mendeley Careers

We’re hiring Bioinformatics Scientists with strong backgrounds in database development, management and analysis as they relate to human health and disease biomarkers, with the goal of improving disease prediction and prevention. With ICR, you’ll get to: Design, build, test and refine multiple large biomarker databases in collaboration with multiple ICR…

Continue Reading Scientist, Bioinformatics – Leonia | Mendeley Careers

Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

Oral and Poster Abstracts 617. Acute Myeloid Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster III Translational Research Maher Albitar, MD1*, Andrew Ip, MD, MSc2, Andre H. Goy, MD3*, Jeffrey Justin Estella, BS, MS1*, Ivan De Dios, BS1*,…

Continue Reading Reliability of Cell-Free DNA (cfDNA) Next Generation Sequencing in Predicting Chromosomal Structural Abnormalities and Cytogenetic-Risk Stratification of Patients with Myeloid Neoplasms

PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

The discovery of a large population of long, cell-free DNA (cfDNA) molecules in maternal plasma, along with a method to identify the molecules’ tissues of origin, is reported in this week Proceedings of the National Academy of Sciences. To date, studies of circulating cfDNA have focused on short molecules of…

Continue Reading PNAS Papers on Long Cell-Free DNA in Maternal Plasma, Genetic Propensity for Voting

What is the Liquid Biopsy, How’s it provided, and what is the Role of the Pulmonologist?

Non–small cell lung carcinoma is the most prevalent kind of lung cancer, and it is also the disease that causes the most fatalities globally each year. The liquid biopsy is the most recent step forward in personalized medicine in cancer therapy, allowing treatment depending on driver mutations found within a…

Continue Reading What is the Liquid Biopsy, How’s it provided, and what is the Role of the Pulmonologist?

Clinical Limit of Detection May Represent Viable cfDNA Metric For Detection of Multiple Cancers

Data were taken from a prospective, multi-center, observational study (NCT02889978), which evaluated cell-free DNA multi-omics in prototype cfDNA-based multi-cancer early detection tests. In the study, researchers collected plasma and matched white blood cells before sequencing them from CCGA study participants (n = 2,800). Tumor biopsies were also sequenced when available….

Continue Reading Clinical Limit of Detection May Represent Viable cfDNA Metric For Detection of Multiple Cancers

cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection. Clinical limit of detection (cLOD) may be a reasonable metric for evaluating cell-free DNA (cfDNA) for multi-cancer early detection, according to recent data from the Circulating Cell-Free Genome Atlas (CCGA) study (NCT02889978). In…

Continue Reading cLOD May Provide More Accurate Evaluation of Cell-Free DNA in Multi-Cancer Early Detection

BioSpace hiring Scientist, Bioinformatics in Leonia, New Jersey, United States

We’re hiringBioinformatics Scientists with strong backgrounds in database development, management and analysis as they relate to human health and disease biomarkers, with the goal of improving disease prediction and prevention. With ICR, You’ll Get To Design, build, test and refine multiple large biomarker databases in collaboration with multiple ICR teams…

Continue Reading BioSpace hiring Scientist, Bioinformatics in Leonia, New Jersey, United States

Senior Bioinformatics Engineer | United States

Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. To bolster our oncology products, we are looking for a Senior Bioinformatics Engineer to provide technical leadership and process guidance. Through collaboration between the product and development teams, the Senior…

Continue Reading Senior Bioinformatics Engineer | United States

New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

HAYWARD, Calif., Sept. 16, 2021 /PRNewswire-PRWeb/ — Predicine, Inc. announced today results from a liquid biopsy study demonstrating the clinical application of utilizing the PredicineCARE liquid biopsy NGS assay to serially monitor changes in ctDNA levels in patients with metastatic castration-resistant prostate cancer (mCRPC). The European Urology study evaluated the effects…

Continue Reading New publication in European Urology demonstrates value of PredicineCARE liquid biopsy test for monitoring PD-L1 immunotherapy in patients with metastatic prostate cancer | News

The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Next-Generation Sequencing Utilizing Tumor Tissue and/or Blood The identification of actionable genomic alterations in tumors such as mCRC was once performed by Sanger DNA sequencing of tumor DNA that was extracted from fixed paraffin-embedded tumor tissue, but this has now been replaced by next-generation sequencing (NGS), which allows for larger-scale…

Continue Reading The Current Molecular Treatment Landscape of Advanced Colorectal Cancer and Need for the COLOMATE Platform

Novel Test Distinguishes Benign From Malignant Lesions in NF1

A novel liquid biopsy test has been shown to distinguish between patients with neurofibromatosis type 1 (NF1) who have benign plexiform neurofibroma (PN) precursor lesions from patients who have malignant peripheral nerve sheath tumors (MPNST), say authors of a multi-institutional cross-sectional study. “Transformation from PN to MPNST is challenging to…

Continue Reading Novel Test Distinguishes Benign From Malignant Lesions in NF1

Science Papers Uncover Protein Involved in Tumor Metastasis, Cancer Detection Via DNA Methylation Sequencing

Using a temporal multi-omics approach, a team led by scientists from Heidelberg University has identified a protein involved in tumor metastasis that could serve as a new therapeutic cancer target. Metastasis is the leading cause of cancer-related mortality and the mechanistically least well-understood step of the tumor progression cascade. However,…

Continue Reading Science Papers Uncover Protein Involved in Tumor Metastasis, Cancer Detection Via DNA Methylation Sequencing

Bioinformatics Engineer | San Carlos, CA

Date posted: Aug 28, 2021 Natera™ is a global leader in cell-free DNA (cfDNA) testing with a focus on women’s health, oncology, and organ health. To bolster our oncology solutions, we are looking for a Bioinformatics Engineer to provide analytical and data management support for Natera’s oncology product. The Bioinformatics…

Continue Reading Bioinformatics Engineer | San Carlos, CA

AI Blood Test Shown to Detect >90% of Lung Cancers Across Different Stages

A novel artificial intelligence (AI) blood testing technology developed by researchers at the Johns Hopkins Kimmel Cancer Center has been shown to detect over 90% of lung cancers in samples from nearly 800 individuals with and without cancer. The test approach, called DELFI (DNA evaluation of fragments for early interception), spots unique…

Continue Reading AI Blood Test Shown to Detect >90% of Lung Cancers Across Different Stages

Thermo Fisher Scientific hiring Bioinformatics Scientist in South San Francisco, California, United States

Job Title; Bioinformatics Scientist, DNA Sequencing Position Location: South San Francisco, CA As a bioinformatics scientist / engineer developing applications in oncology, personalized medicine, inherited disease, and viral/microbial genetics, you will play a key role in developing, improving, and expanding analysis solutions for next-generation DNA sequencing products. Primary responsibilities will…

Continue Reading Thermo Fisher Scientific hiring Bioinformatics Scientist in South San Francisco, California, United States